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INTRODUCTION
Cardiac resynchronization therapy (CRT) is an important ther-
apeutic option for patients with heart failure (HF) and left ven-
tricular (LV) dyssynchrony.1,2 However, approximately one-
third of patients do not respond to CRT. The definition of CRT 
response is challenging. Although several clinical, echocar-
diographic, and hemodynamic criteria have been suggested, 
how and when to define CRT response remains controversial. 
Recently, many researchers have used changes in LV end-sys-
tolic volume (LVESV) at 6 or 12 months as CRT response crite-
ria. However, there is a lack of evidence confirming that change 
in LVESV is a clinically useful criterion for the determination 
of CRT response. The ultimate goals of HF treatment are to re-
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lieve symptoms, maintain clinical stability, and prevent car-
diovascular mortality. Therefore, clinical outcomes are impor-
tant end points for the evaluation of HF treatment. However, it 
is difficult to apply event-driven clinical criteria, including 
hard end points, to an individual patient in daily clinical prac-
tice. Echocardiography is widely used to assess cardiac func-
tion in HF clinic. Therefore, it is important to elucidate which 
echocardiographic CRT response criteria have significant accu-
racy to enable discrimination of symptoms and clinical out-
comes. The echocardiographic criteria that provide significant 
accuracy for the discrimination of clinical outcomes might be 
predictors of long-term prognosis in patients receiving CRT. 
The hierarchical clinical composite end point (HCCEP) was 
designed for the assessment of clinical course of HF by com-
bining symptoms, clinical stability, and mortality3 and is rec-
ognized to be suitable for the evaluation of new drugs, devices, 
and procedures for HF management. The present study aimed 
to elucidate which echocardiographic CRT response criteria 
at three time points are significantly accurate in discriminating 
improvement in 1-year HCCEP and have significant agreement 
with improvement in 1-year HCCEP, as well as to determine 
the optimal cutoff value for improvement in 1-year HCCEP.
MATERIALS AND METHODS
Study population and HCCEP
The study design was approved by the Institutional Review 
Board (IRB no. 1-2013-0061), and the current study was per-
formed in compliance with the ethical principles outlined in 
Declaration of Helsinki. We included 120 consecutive patients 
(mean age, 66.1±12.6 years; men, 54.2%) in Severance CRT 
registry who underwent CRT implantation for HF from Janu-
ary 2010 to June 2017. CRT implantation was performed in ac-
cordance with the guidelines for HF management: LV ejection 
fraction (LVEF) ≤35%, QRS duration ≥130 ms, and New York 
Heart Association (NYHA) functional class II, III, or ambula-
tory IV despite optimal medical therapy for ≥3 months.1,2 Pa-
tients lost to follow-up within 12 months after CRT implanta-
tion or in whom CRT device was removed within 12 months 
were excluded. At implantation, CRT was optimized based on 
the intracardiac electrogram from CRT leads. After CRT im-
plantation, patients were followed up at the outpatient clinic 
every 3 months, and optimal medical therapy for HF was main-
tained. At every visit, patients’ symptoms and NYHA functional 
class were assessed, and CRT interrogation and optimization 
based on the intracardiac electrogram were performed. The 
1-year HCCEP included all-cause mortality, hospitalization 
for HF, and change in NYHA functional class for 12 months 
since CRT implantation. Patients were classified into improved, 
unchanged, and worsened, based on the 1-year HCCEP.3 Pa-
tients were considered to have improved if they experienced 
improvement in NYHA functional class and did not experi-
ence mortality and hospitalization for HF. Moreover, patients 
were considered to have worsened if they experienced mor-
tality due to any cause, hospitalization for HF, or worsening in 
NYHA functional class. Finally, patients were considered to 
have remained unchanged if they did not either improve or 
worsen (i.e., had no change in their symptoms and did not ex-
perience mortality and hospitalization for HF).
Echocardiography
Transthoracic echocardiography was performed before and 
at 3 (range: 2–4), 6 (range: 5–7), and 12 (range: 10–14) months 
after CRT implantation. LV end-diastolic volume (LVEDV) and 
LVESV were measured using biplane disc method from apical 
4- and 2-chamber views. LVEF was calculated as (LVEDV-
LVESV)×100/LVEDV. Mitral regurgitation (MR) was graded as 
mild, moderate, and severe based on Doppler echocardiogra-
phy using the standard criteria provided by American Society 
of Echocardiography.4 The symbol  Δ at t months was defined 
as difference between values at t months after CRT implanta-
tion and before CRT implantation. Absolute ΔLVEF at t months 
was defined as (LVEF at t months)-(LVEF before CRT implan-
tation). Relative ΔLVEF at t month was defined as [(LVEF at t 
month)-(LVEF before CRT implantation)]×100/(LVEF before 
CRT implantation). ΔLVESV, ΔLVEDV, absolute ΔLVEF, relative 
ΔLVEF, and ΔMR at 3, 6, and 12 months were measured and 
calculated. The echocardiographic CRT response criteria were 
follows: decrease in LVESV >15%,5-7 decrease in LVEDV >15%,5 
absolute increase in LVEF ≥5%,5,8 relative increase in LVEF 
≥15%,9,10 and decrease in MR ≥1 grade.11,12
Statistical analyses of data
Results are expressed as median (interquartile range) for con-
tinuous data and number and percentage for categorical data. 
Patients were divided into two groups according to the cause 
of HF: nonischemic and ischemic groups. We compared the 
clinical parameters between both groups using Fisher’s exact 
test for categorical data, and Mann-Whitney U test for contin-
uous data. Temporal trends in CRT response rates according to 
echocardiographic criteria were analyzed in total, nonischemic, 
and ischemic groups. The generalized linear model for re-
peated measures was used for the analyses of temporal chang-
es in CRT response rates. Bonferroni correction was used for 
post-hoc analyses. The area under the curve (AUC) in receiver 
operating characteristics (ROC) curve was used to analyze the 
accuracy of echocardiographic CRT response criteria at 3, 6, 
and 12 months for discrimination of improvement from no im-
provement (no change and worsening) in HCCEP. AUC was ex-
pressed as area [95% confidence interval (CI)]. An AUC >0.75 
was considered clinically significant. The optimal cutoff value 
of echocardiographic CRT response criteria was estimated 
based on the probability that the combination of sensitivity and 
specificity was maximized in the model. The echocardiograph-
ic CRT response criteria were analyzed for agreement with im-
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provement in HCCEP using Cohen’s κ coefficient. A κ statistic 
≤0 was considered poor agreement; 0<κ≤0.2, slight agreement, 
0.2<κ≤0.4, fair agreement; 0.4<κ≤0.6, moderate agreement; 
0.6<κ≤0.8, substantial agreement; 0.8<κ<1.0, almost perfect 
agreement; and 1, perfect agreement.13 A p value <0.05 was 
considered significant. Data were analyzed using Statistical 
Package for the Social Sciences, version 23.0 (IBM Corp., Ar-
monk, NY, USA).
RESULTS
Study population
Table 1 shows baseline characteristics and HCCEP of patients 
in total, nonischemic, and ischemic groups. Nonischemic and 
ischemic groups comprised 95 (79.2%) and 25 (20.8%) pa-
tients, respectively. The prevalence of diabetes and right bun-
dle branch block was significantly higher in ischemic group 
than in nonischemic group. No significant differences in other 
baseline characteristics were observed between nonischemic 
and ischemic groups. Follow-up echocardiography was per-
formed at 3, 6, and 12 months in 110, 97, and 94 patients, re-
spectively. In total group, improvement, no change, and wors-
ening rates of HCCEP after CRT implantation were 65.8, 3.3, 
and 30.8%, respectively. Furthermore, 6.7, 13.3, and 25.8% of 
patients experienced all-cause mortality, hospitalization for 
HF, and aggravation in the NYHA functional class for 12 months. 
No patient underwent heart transplantation within 12 months 
after CRT implantation. There were no significant differences 
in the rate of improvement in HCCEP between nonischemic 
and ischemic groups.
Temporal changes in CRT response
Fig. 1 shows the temporal changes in CRT response rates ac-
cording to echocardiographic criteria at 3, 6, and 12 months 
in total, nonischemic, and ischemic groups. In total group, 
CRT response rates according to all echocardiographic crite-
ria significantly increased with time up to 12 months after 
CRT implantation. CRT response rates at 12 months were 
67.8, 55.6, 70.2, 76.6, and 48.4% according to ΔLVESV, ΔLVEDV, 
absolute ΔLVEF, relative ΔLVEF, and ΔMR, respectively. In 
nonischemic group, CRT response rates according to all echo-
cardiographic criteria significantly increased with time up to 12 
months, except for the CRT response rate according to ΔLVEDV 
from 6 to 12 months. CRT response rates at 12 months were 
68.9, 55.4, 76.6, 83.1, and 50.0%, according to ΔLVESV, ΔLVEDV, 
absolute ΔLVEF, relative ΔLVEF, and ΔMR, respectively. In 
ischemic group, CRT response rates according to any echo-
Table 1. Baseline Characteristics and 1-Year HCCEP of the Study Population
Total (n=120) Nonischemic (n=95) Ischemic (n=25) p value*
Age (yr) 69.5 (59.0, 74.0) 69.0 (59.0, 74.0) 71.0 (65.5, 74.5) 0.627
Male 65 (54.2) 49 (51.2) 16 (64.0) 0.267
NYHA functional class 3.0 (2.0, 3.0) 3.0 (2.0, 3.0) 3.0 (2.0, 3.0) 0.303
Hypertension 60 (50.0) 44 (46.3) 16 (64.0) 0.116
Diabetes 59 (49.2) 42 (44.2) 17 (68.0) 0.034
Atrial fibrillation 21 (17.5) 17 (17.9) 4 (16.0) >0.999
AV node ablation 8 (38.1) 5 (29.4) 3 (75.0) 0.253
QRS complex
Duration (ms) 164.0 (150.5, 180.0) 164.0 (152.0, 182.0) 158.0 (148.0, 175.0) 0.721
LBBB 85 (70.8) 69 (72.6) 16 (64.0) 0.398
RBBB 10 (8.3) 5 (5.3) 5 (20.0) 0.032
IVCD 13 (10.8) 12 (12.6) 1 (4.0) 0.297
Pacing-dependent 12 (10.0) 9 (9.5) 3 (12.0) 0.733
Baseline LVEF (%) 24.5 (20.0, 30.0) 24.0 (20.0, 30.0) 25.0 (22.0, 30.0) 0.480
Defibrillator 97 (80.8) 76 (80.0) 21 (84.0) 0.781
Secondary prevention 5 (5.2) 4 (4.2) 1 (4.0) >0.999
Medication use for HF
ACEI/ARB 107 (89.2) 85 (89.5) 22 (88.0) 0.833
β-blocker 92 (76.7) 71 (74.7) 21 (84.0) 0.330
MRA 76 (63.3) 62 (65.3) 14 (56.0) 0.392
Improvement in HCCEP 79 (65.8) 63 (66.3) 16 (64.0) 0.772
ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; AV, atrioventricular; HCCEP, hierarchical clinical composite end point; HF, heart 
failure; IVCD, intraventricular conduction delay; LBBB, left bundle branch block; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antago-
nist; NYHA, New York Heart Association; RBBB, right bundle branch block.
Data are expressed as median (interquartile range) or number (percent).
*Comparison between nonischemic and ischemic groups.
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cardiographic criteria did not significantly change with time 
up to 12 months. CRT response rates at 12 months were 62.5, 
56.3, 41.2, 47.1, and 41.2% according to ΔLVESV, ΔLVEDV, abso-
lute ΔLVEF, relative ΔLVEF, and ΔMR, respectively.
Accuracy and optimal cutoff value of 
echocardiographic CRT response criteria 
for the discrimination of 1-year HCCEP
In total group, ΔLVESV and ΔLVEDV at 6 months showed clini-
cally significant accuracy for the discrimination of improve-
ment in 1-year HCCEP [AUC=0.781 (95% CI, 0.653–0.909) and 
0.778 (95% CI, 0.647–0.909), respectively] (Fig. 2). In nonisch-
emic group, ΔLVEDV and ΔLVESV at 6 months showed clini-
cally significant accuracy [AUC=0.776 (95% CI, 0.620–0.931) 
and 0.756 (95% CI, 0.594–0.918), respectively] (Supplementary 
Table 1, only online). In ischemic group, ΔLVESV at 6 and 12 
months showed clinically significant accuracy [AUC=0.875 
(95% CI, 0.683–1.000) and 0.792 (95% CI, 0.548–1.000), respec-
tively] (Supplementary Table 1, only online). Other echocardio-
graphic CRT response criteria did not show clinically signifi-
cant accuracy. Since ΔLVESV at 6 months had the largest AUC 
among all echocardiographic CRT response criteria in total 
group, the cutoff value of ΔLVESV at 6 months for the discrim-
ination of improvement in 1-year HCCEP was estimated and 
determined to be 13.5%, which provided the maximized com-
bination of sensitivity and specificity (0.719 and 0.719, respec-
tively) (Fig. 2A). When the cutoff value of ΔLVESV at 6 months 
was set as 15%, sensitivity and specificity were 0.687 and 0.719, 
respectively.
Agreement of echocardiographic CRT response 
criteria with 1-year HCCEP
Fig. 3 shows the agreements of echocardiographic CRT response 
criteria at 3, 6, and 12 months with improvement in 1-year 
HCCEP in total group. In total group, ΔLVESV and ΔLVEDV at 6 
months had significantly fair agreement with improvement in 
Fig. 1. Temporal changes in CRT response rates according to (A) ΔLVESV, (B) ΔLVEDV, (C) absolute ΔLVEF, (D) relative ΔLVEF, and (E) ΔMR in total, nonisch-
emic, and ischemic groups. p values indicate the statistical significance of temporal changes in CRT response rates according to each echocardiograph-
ic CRT response criterion in each group from 3 to 12 months. *The temporal change in CRT response, based on ΔLVEDV from 6 to 12 months, in nonisch-
emic group is insignificant in post-hoc analysis. CRT, cardiac resynchronization therapy; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular 
ejection fraction; LVESV, left ventricular end-systolic volume; MR, mitral regurgitation.
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1-year HCCEP (κ=0.391, p<0.001 and κ=0.340, p=0.001, respec-
tively). Similarly, ΔLVESV at 12 months had significantly fair 
agreement (κ=0.223, p=0.034). In nonischemic group, ΔLVESV 
and ΔLVEDV at 6 months had significantly fair agreement 
(κ=0.363, p=0.002, and κ=0.376, p=0.001, respectively) (Supple-
mentary Table 2, only online). In ischemic group, ΔLVESV at 3 
and 6 months had significantly fair and moderate agreement, 
respectively (κ=0.373, p=0.039, and κ=0.468, p=0.019, respec-
tively) (Supplementary Table 2, only online). However, abso-
lute ΔLVEF, relative ΔLVEF, and ΔMR at any time did not have 
any significant agreement with improvement in 1-year HC-
CEP in total, nonischemic, and ischemic groups.
DISCUSSION
This was a cohort study using real-world CRT registry data. The 
main findings of the present study are as follows: 1) In non-
ischemic group, CRT response rates increased with time up to 
12 months since CRT implantation. 2) In contrast, in ischemic 
group, CRT response rates were static with time. 3) In total 
group, ΔLVESV at 6 months had the most clinically significant 
accuracy for the discrimination of improvement in 1-year HC-
CEP. 4) The optimal cutoff value of ΔLVESV at 6 months for the 
discrimination of improvement in 1-year HCCEP was 13.5%. 
5) ΔLVESV at 6 months had fair agreement with improvement 
in 1-year HCCEP.
According to Frank-Starling law, stroke volume increases in 
response to an increase in preload. However, if preload is ex-
cessively increased beyond the appropriate range, stroke vol-
ume decreases. If preload is decreased to the appropriate 
range, stroke volume can be recovered. CRT can restore intra-
ventricular, interventricular, and atrioventricular synchrony 
through timely biventricular pacing. Restoration of synchrony 
Fig. 2. Receiver operating characteristic curve and area under the curve of (A) ΔLVESV, (B) ΔLVEDV, (C) absolute ΔLVEF, (D) relative ΔLVEF, and (E) ΔMR for 
the discrimination of improvement in 1-year hierarchical clinical composite end point in total group. When the optimal cutoff value of ΔLVESV at 6 months 
is set as 13.5% (circle), sensitivity and specificity are 0.719 and 0.719, respectively. abs, absolute; AUC, area under the curve; LVEDV, left ventricular end-di-
astolic volume; LVEF, left ventricular ejection fraction; LVESV, left ventricular end-systolic volume; MR, mitral regurgitation; rel, relative.
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can result in improved cardiac performance and output, which, 
in turn, can lead to a decrease in LVESV and LVEDV or reverse 
remodeling. Moreover, reverse remodeling can lead to an ad-
ditional improvement in cardiac performance, since preload 
decreases to the appropriate range. Delayed CRT response 
might occur as the interactions between cardiac performance 
and reverse remodeling can last for several weeks or months. 
According to the results of the present study, CRT response 
rates increased with time in patients with nonischemic HF but 
were static in patients with ischemic HF. In other words, CRT 
response tended to be delayed and early in patients with non-
ischemic and ischemic HF, respectively. The reason for these 
temporal patterns of CRT response is not clear. A previous 
study reported that greater myocardial scar burden might be 
related to incidence of delayed CRT response.14 Although myo-
cardial scarring was not measured in this study, a tentative ex-
planation for the temporal changes in CRT response in non-
ischemic and ischemic HF could be that nonischemically 
failing heart probably has diffuse myocardial fibrosis, whereas 
ischemically failing heart probably has regional myocardial fi-
brosis. Diffuse myocardial fibrosis might be related to delayed 
CRT response. Contrary to the results of this study, a previous 
study reported no significant difference in the time course of 
CRT response between nonischemic and ischemic HF.15 An-
other study indicated that ischemic HF was a predictor of late 
LV reverse remodeling.16 Since temporal CRT response pat-
terns and their mechanisms remain controversial, more stud-
ies need to be conducted.
Controversy exists as to when to assess CRT response. The 
present study suggested that the appropriate time to assess 
CRT response is 6 months after CRT implantation. This may be 
due to reverse remodeling lasting for several weeks or months. 
The reason behind the lower accuracy and agreement of ΔLVESV 
at 12 months with HCCEP than those at 6 months in patients 
with nonischemic HF, despite an increase in CRT response 
rate, is unclear. Approximately half of patients with nonisch-
emic HF who became responders between 6 and 12 months 
had worsening HCCEP owing to hospitalization for HF. The 
insignificant agreement of ΔLVESV at 12 months in patients 
with ischemic HF might be attributed to the small number of 
patients. In summary, it is reasonable that CRT response should 
be assessed at 6 months after CRT implantation in patients 
with nonischemic and ischemic HF.
The definitions of CRT response were not consistent across 
several large clinical trials on CRT. In early clinical trials on CRT, 
symptomatic and clinical outcome criteria, including hospi-
talization for HF and mortality, have been studied as CRT out-
comes.7,17-19 In later studies, echocardiographic, hemodynam-
ic, and neurohormonal criteria were also investigated as CRT 
outcomes.12,17,19,20 Several studies have been performed to eval-
uate agreements among CRT response criteria. PROSPECT 
study reported that CRT response rate according to clinical 
composite score was higher than that according to change in 
LVESV.6 Another study indicated poor agreements among clini-
cal and echocardiographic CRT response criteria.21 When im-
provement in NYHA functional class and CRT response ac-
cording to echocardiographic criteria were compared, patients 
with improved NYHA functional class and no echocardio-
graphic response mainly contributed to the disagreement.5 
HCCEP is a composite end point that combines symptoms, 
clinical stability, and mortality within a certain period in pa-
tients with HF.3 HCCEP is not a scoring system that includes 
arbitrary weights to clinical factors. Patients with HF can be 
comprehensively classified according to whether they exhib-
Fig. 3. Agreements of echocardiographic CRT response criteria at each time with improvement in 1-year hierarchical clinical composite end point in total 
group. *p<0.05. Abs, absolute; CRT, cardiac resynchronization therapy; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; 
LVESV, left ventricular end-systolic volume; MR, mitral regurgitation; Rel, relative.
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ited improvement, no change, and worsening using HCCEP 
after a certain period of HF treatment. Therefore, HCCEP can 
be a standard end point for the assessment of CRT response 
criteria.6
In the present study, ΔLVESV at 6 months was the most clini-
cally useful echocardiographic CRT response criterion, since 
it had the largest AUC in ROC curve for the discrimination of 
improvement in 1-year HCCEP and had fair agreement with 
improvement in 1-year HCCEP. As the optimal cutoff value of 
ΔLVESV at 6 months was 13.5% in ROC curve, the usage of 
13.5% as the cutoff value of ΔLVESV in clinical practice and 
studies is reasonable. An improvement in LV synchrony and 
systolic function directly leads to a decrease in LVESV. Reverse 
remodeling means decreases in LVESV and LVEDV. Therefore, 
change in LVESV is linked to both LV systolic function and re-
verse remodeling. This could be the reason why ΔLVESV is sig-
nificantly associated with clinical outcomes and most relevant 
echocardiographic CRT response criteria. In contrast, LVEDV 
is not directly related to LV systolic function. Although ΔLVEDV 
at 6 months had higher accuracy and agreement than ΔLVESV 
at 6 months in patients with nonischemic HF, the use of ΔLVESV 
would be feasible. This is due to the necessity to use the same 
criteria in nonischemic and ischemic HF.
The reason for poor agreement of absolute and relative ΔLVEF 
is not clear. The likely explanations are as follows. Measure-
ments of LVEDV and LVESV using biplane disc method are de-
pendent on geometric assumptions. Ignorable differences be-
tween geometric assumption and real geometry, and ignorable 
measurement errors could be included in echocardiographic 
measurements. Since LVEF was calculated using LVEDV and 
LVESV, the ignorable differences and errors might have been 
summated and become unignorable while calculating LVEF. 
Generally, as HF progresses, LV is dilated. LV dilation results 
in functional (or secondary) MR. As a result, functional MR se-
verity can be associated with HF severity. However, it is occa-
sionally difficult to discriminate functional MR from organic 
(or primary) MR that is not caused by LV dilation. Additionally, 
in patients with no or trivial MR before CRT implantation, the 
ΔMR criterion cannot differentiate CRT responders from pa-
tients with a steady state. In the present study, 33.3% of pa-
tients in total group had no MR before CRT implantation. The 
low CRT response rate according to the ΔMR criterion and the 
poor accuracy and agreement of ΔMR could be attributed to 
the inclusion of a considerable number of patients with no or 
trivial MR or those with organic MR. 
The present study has several limitations. This was a cohort 
study using real-world CRT registry data, rather than a prospec-
tive study. The number of patients was not large; in particular, 
the number of patients with ischemic HF was small. Objective 
measurements of patients’ functional capacity, including the 
6-min walking test, cardiopulmonary exercise test, and quality-
of-life score, were not included since these were serially per-
formed in only a small number of patients. All patients did not 
undergo echocardiography three times. QRS morphology 
(true left bundle branch block or not), LV lead position, and 
percentage of biventricular pacing were not included in the 
analyses despite being important factors for the determina-
tion of CRT response. 
In conclusion, a decrease in LVESV at 6 months >13.5% is 
the most clinically useful echocardiographic CRT response 
criterion for the prediction of 1-year HCCEP.
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